Consultant

More than 30 years of experience successfully leading product development and strategic partnering

Dr. Gringeri’s track record includes biologics and gene therapies, which were new technologies to both U.S. and European regulators at the time of their development

Dr. Gringeri spent more than 14 years at Amgen in various executive positions, managing diverse functions including serving as Vice President, Product Development, Vice President, Scientific Outreach and Licensing Operations, and Vice President, Project Management & Strategic Planning. Early on Dr. Gringeri was the Product Development Team Leader overseeing Amgen’s blockbuster drug, ARANESP®

Dr. Gringeri was the Chief Operating Officer for Amsterdam Molecular Therapeutics (AMT), a Netherlands-based company engaged in human gene therapies for orphan diseases related to metabolic disorders, liver diseases, blood diseases, and disorders of the central and peripheral nervous systems

Most recently, Dr. Gringeri served as Chief Executive Officer at ImmunoCellular Therapeutics, an immuno-oncology company investigating dendritic cell-based therapies in the treatment of brain and ovarian cancer